This study is a single-center, randomized, open-label, two-period crossover design to evaluate the effect of food on the pharmacokinetic profile of ammoxetine hydrochloride enteric-coated tablets.

Inclusion Criteria:

1. Age: 18-45 years (inclusive), both male and female subjects;
2. Body weight ≥ 45.0 kg (female) or 50.0 kg (male), with body mass index (BMI) between 19.0 kg/m² and 26.0 kg/m² (inclusive);
3. Results of medical history, vital signs, physical examination, and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and other relevant tests) are normal or abnormal but without clinical significance;
4. Subjects and their partners must use effective non-hormonal contraceptive methods (e.g., condoms, non-hormonal intrauterine devices) from 2 weeks prior to screening until 6 months after the study completion, except for those who have already adopted permanent contraceptive measures (e.g., bilateral tubal ligation, vasectomy). Donation of sperm or eggs is also prohibited during this period;
5. Voluntarily sign the informed consent form and be willing to comply with the protocol to complete the study.

Exclusion Criteria:

1. Subjects with a history of allergies (allergic to two or more types of drugs, foods, or pollen);
2. Subjects suffering from psychiatric disorders, hepatic or renal diseases, gastrointestinal diseases, neurological diseases, or other systemic diseases;
3. Subjects with clinically significant abnormalities confirmed by comprehensive examinations including medical history, physical examination, electrocardiogram, and chest X-ray;
4. Subjects with systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg during the screening period;
5. Subjects with orthostatic hypotension;
6. Subjects with corrected QT interval (QTc) ≥ 450 ms (male) or ≥ 470 ms (female), or a history of prolonged QTc interval;
7. Subjects with a history of smoking or alcohol abuse (consumption of 14 units of alcohol per week within the 4 weeks prior to screening: 1 unit = 285 mL beer, or 25 mL spirits, or 150 mL wine; daily smoking ≥ 5 cigarettes) or other substance or drug abuse within the past year;
8. Subjects who have donated or lost more than 400 mL of blood within the 8 weeks prior to screening;
9. Subjects who have participated in other clinical trials within the 3 months prior to screening;
10. Subjects who habitually consume excessive amounts of caffeinated beverages or foods within the 4 weeks prior to screening, such as coffee, tea, chocolate, cola, or Red Bull (daily caffeine intake not exceeding 6 units). 1 caffeine unit = 1 cup of coffee (177.4 mL) = 2 cans of cola (354.9 mL) = 1 cup of tea (354.9 mL) = 1/2 cup of energy drink = 85 g chocolate;
11. Subjects who have used medications that alter the activity of liver enzymes (Cytochrome P450 2C19 and Cytochrome P450 3A4) within the 4 weeks prior to screening, such as dexamethasone, ketoconazole, rifampicin, omeprazole, or grapefruit
12. Subjects who have used prescription drugs, over-the-counter medications (except for occasional use of acetaminophen and nasal sprays), herbal remedies, vitamins, or minerals within the 2 weeks prior to screening, or for whom the washout period of prior medications (based on the longest half-life) is less than 5 half-lives before screening;
13. Subjects using any psychiatric medications or psychoactive substances;
14. Pregnant or lactating women, or female subjects with a positive pregnancy test during the screening period;
15. Subjects who have already participated in this trial;
16. Subjects considered by the investigator to have any factors that make them unsuitable for participation in this trial.